194 related articles for article (PubMed ID: 31196186)
1. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
Tataranni T; Mazzoccoli C; Agriesti F; De Luca L; Laurenzana I; Simeon V; Ruggieri V; Pacelli C; Della Sala G; Musto P; Capitanio N; Piccoli C
Stem Cell Res Ther; 2019 Jun; 10(1):171. PubMed ID: 31196186
[TBL] [Abstract][Full Text] [Related]
2. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
[TBL] [Abstract][Full Text] [Related]
5. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN.
Lee HJ; Oh YK; Rhee M; Lim JY; Hwang JY; Park YS; Kwon Y; Choi KH; Jo I; Park SI; Gao B; Kim WH
J Mol Biol; 2007 Jun; 369(4):967-84. PubMed ID: 17475277
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
[TBL] [Abstract][Full Text] [Related]
7. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth.
Kato K; Kamezaki K; Shimoda K; Numata A; Haro T; Aoki K; Ishikawa F; Takase K; Ariyama H; Matsuda T; Miyamoto T; Nagafuji K; Gondo H; Nakayama K; Harada M
Br J Haematol; 2003 Nov; 123(3):528-35. PubMed ID: 14617019
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side.
Prieto-Bermejo R; Romo-González M; Pérez-Fernández A; Ijurko C; Hernández-Hernández Á
J Exp Clin Cancer Res; 2018 Jun; 37(1):125. PubMed ID: 29940987
[TBL] [Abstract][Full Text] [Related]
9. Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events.
Singh N; Lawana V; Luo J; Phong P; Abdalla A; Palanisamy B; Rokad D; Sarkar S; Jin H; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2018 Sep; 117():82-113. PubMed ID: 29859868
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
[TBL] [Abstract][Full Text] [Related]
11. Effects of iron overload on the bone marrow microenvironment in mice.
Zhang Y; Zhai W; Zhao M; Li D; Chai X; Cao X; Meng J; Chen J; Xiao X; Li Q; Mu J; Shen J; Meng A
PLoS One; 2015; 10(3):e0120219. PubMed ID: 25774923
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
Shen JC; Zhang YC; Zhao MF
Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox protects against hydrogen peroxide-induced cell apoptosis by inhibiting ubiquitination and degradation of p21
Miao J; Xu M; Kuang Y; Pan S; Hou J; Cao P; Duan X; Chang Y; Hasem H; Zhou N; Tan K; Fan Y
Biochem Biophys Res Commun; 2020 Apr; 524(3):736-743. PubMed ID: 32035614
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
[TBL] [Abstract][Full Text] [Related]
15. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34
Shapira S; Raanani P; Samara A; Nagler A; Lubin I; Arber N; Granot G
Exp Hematol; 2019 Feb; 70():55-69.e4. PubMed ID: 30414989
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
Pullarkat V; Sehgal A; Li L; Meng Z; Lin A; Forman S; Bhatia R
Leuk Res; 2012 Aug; 36(8):966-73. PubMed ID: 22502920
[TBL] [Abstract][Full Text] [Related]
18. Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.
Dubois A; Ginet C; Furstoss N; Belaid A; Hamouda MA; El Manaa W; Cluzeau T; Marchetti S; Ricci JE; Jacquel A; Luciano F; Driowya M; Benhida R; Auberger P; Robert G
Oncotarget; 2016 May; 7(18):26120-36. PubMed ID: 27027430
[TBL] [Abstract][Full Text] [Related]
19. The pyridone-annelated isoindigo (5'-Cl) induces apoptosis, dysregulation of mitochondria and formation of ROS in leukemic HL-60 cells.
Saleh AM; Aljada A; El-Abadelah MM; Sabri SS; Zahra JA; Nasr A; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1958-74. PubMed ID: 25871324
[TBL] [Abstract][Full Text] [Related]
20. Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.
Kaowinn S; Jun SW; Kim CS; Shin DM; Hwang YH; Kim K; Shin B; Kaewpiboon C; Jeong HH; Koh SS; Krämer OH; Johnston RN; Chung YH
Cell Oncol (Dordr); 2017 Dec; 40(6):549-561. PubMed ID: 28776259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
